Capillary tube leukocyte adherence inhibition: an assay for cell-mediated immunity in cancer patients.
The leukocyte adherence inhibition (LAI) assay has been modified and automated in order to facilitate its clinical application. This new assay-the capillary tube LAI test-correlated with delayed cutaneous hypersensitivity using streptokinase-streptodornase antigen in 83% of the cases. When tested with a 3 M KC1 lung carcinoma antigen, lung carcinoma patients' leukocytes were more frequently inhibited (55%) than those of controls (normals 6%, other tumors 20%).